C.R. Bard
http://www.crbard.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From C.R. Bard
FDA Approves First Ophthalmic Biosimilar With Samsung Bioepis’ Lucentis Rival
Samsung Bioepis has celebrated the FDA’s first ever approval of an ophthalmic biosimilar with its endorsement of the firm’s Byooviz ranibizumab rival to Lucentis. The firm has also signaled a surprising expected launch date in the US, as well as offering expectations for launch in Europe where the biosimilar was also recently approved.
Wet AMD Market Snapshot: A High-Growth Market Poised For Change
Regeneron's Eylea and Roche's Lucentis currently dominate the treatment market for wet-AMD and diabetic eye disease, but biosimilar ranibizumab and new brand launches are on the horizon.
Samsung Bioepis Boasts Positive Data On Lucentis And Herceptin Biosimilars
Ahead of launching potentially its Lucentis biosimilar in the EU early next year, Samsung Bioepis has reported two lots of positive analysis involving its Byooviz biosimilar, at the same time as it disclosed the findings of a five-year follow-up study for its trastuzumab biosimilar, Ontruzant.
Samsung Bioepis Toasts First Bevacizumab Biosimilar In Korea
Samsung Bioepis has expanded its portfolio of biosimilar products in its domestic South Korea, with the launch of bevacizumab via partner Boryung Pharmaceutical.
Company Information
- Industry
- Medical Devices
- Other Names / Subsidiaries
-
- Davol, Inc.
- Embo Medical Limited
- Liberator Medical, Inc.
- Lutonix, Inc.
- Medafor, Inc.
- Medicon, Inc.
- Neomend, Inc.
- Rochester Medical, Inc.
- Vascular Pathways, Inc.
- FlowCardia, Inc.
- Bridger Biomed, Inc.